A government agency based in the UK has updated its health warnings regarding Pradaxa (dabigatran), suggesting that healthcare professional may not want to use the blood thinning medication for certain types of patients.
The Medicines and Healthcare products Regulatory Agency (MHRA) recently updated its advice on contraindications – which is defined as “something (as a symptom or condition) that makes a particular treatment or procedure inadvisable” – and warnings to include significant bleeding risk notices when it is taken by people with certain clinical conditions. They include:
- Current or recent gastrointestinal ulceration
- Malignant neoplasms
- Recent brain or spinal injury
- Recent brain, spinal or ophthalmic surgery
- Recent intracranial haemorrhage
- Oesophageal varices
- Arteriovenous malformations
- Vascular aneurysms
- Major intraspinal or intracerebral vascular abnormalities
The new warnings also advised on the safest times to mix in the first dose of dabigatran to a medications schedule, the safest ways to discontinue the use of dabigatran treatments, and a reminder of how important it is for doctors to utilize renal function monitoring in patients using the anticoagulant.
“Renal function should be assessed in all patients before starting dabigatran and at least once a year in patients older than 75 years or those with a suspected decline in renal function,” the warning reads. “Dabigatran is contraindicated in patients with severe renal impairment (creatinine clearance <30 mL/min)."
This is only the latest warning by medical experts that detail the significant bleeding risk that can come with the use of Pradaxa. Check out other stories on our blog to learn more about other warnings that have been issued.